Clinical trials in Cluj Napoca – page 9

The clinical trial landscape in Cluj Napoca is strongly centered on oncology and blood cancers, with studies spanning solid tumors and hematologic malignancies. Major efforts focus on improving treatment effectiveness and long-term outcomes for patients with lung cancer, breast cancer, colorectal cancer, lymphoma, and leukemia.

• Advanced and early-stage non-small cell lung cancer, including biomarker-driven subtypes
• Breast cancer, prostate cancer, and bladder cancer studies
• Lymphoma, multiple myeloma, and leukemia research
• Trials testing new combinations, targeted therapies, and better post-surgery treatment approaches

Many of these studies are designed to refine cancer care by comparing newer therapies with standard treatment and by identifying options for harder-to-treat disease subtypes.

There is also a major focus on respiratory medicine, especially chronic and severe lung disease. Research in this area includes trials for COPD, asthma, bronchiectasis, and interstitial lung disease, aiming to improve symptom control and reduce flare-ups.

• Chronic obstructive pulmonary disease and chronic bronchitis
• Asthma across mild, moderate, and severe forms
• Bronchiectasis and interstitial lung disease
• Studies evaluating better maintenance therapy and new anti-inflammatory approaches

These trials reflect a strong interest in helping patients breathe more easily and lowering the burden of long-term lung disease.

Clinical trials in cardiology and nephrology are exploring ways to lower the risk of heart, vascular, and kidney complications. In Cluj Napoca, this includes studies in heart failure, atrial fibrillation, hypertension, stroke prevention, and chronic kidney disease.

• Heart failure, atrial fibrillation, and atherosclerotic cardiovascular disease
• Chronic kidney disease and kidney-related complications
• Hypertension and vascular risk reduction
• Trials focused on prevention, better control, and fewer cardiovascular events

Several studies are aimed at improving long-term outcomes for patients with overlapping heart and kidney conditions.

Research in digestive diseases and metabolic health is broad, covering inflammatory bowel disease, liver disease, and metabolic dysfunction. Ongoing trials address ulcerative colitis, Crohn’s disease, NASH, hepatitis B, and diabetes, with a clear emphasis on better disease control and organ protection.

• Ulcerative colitis and Crohn’s disease
• Non-alcoholic steatohepatitis and liver fibrosis
• Type 2 diabetes, obesity, and related metabolic conditions
• Trials testing new options to improve symptoms, inflammation, and long-term disease outcomes

These studies highlight a growing interest in treatments that can ease chronic gastrointestinal symptoms while also addressing broader metabolic risk.

A substantial share of research in the city focuses on autoimmune and inflammatory diseases. Trials are studying conditions such as rheumatoid arthritis, systemic lupus erythematosus, psoriasis, systemic sclerosis, and Sjögren’s disease, often with the goal of reducing immune-driven damage and improving daily function.

• Rheumatoid arthritis, psoriatic arthritis, and juvenile psoriatic arthritis
• Systemic lupus erythematosus, systemic sclerosis, and Sjögren’s disease
• Plaque psoriasis, atopic dermatitis, and related skin inflammation
• Studies assessing new immune-targeted treatments for disease control and symptom relief

These trials reflect active research into treatments that may better balance immune suppression with safety and long-term benefit.

In neurology and psychiatry, trials are examining both chronic neurological disease and mental health conditions. Key areas include multiple sclerosis, epilepsy, migraine, ADHD, major depressive disorder, and schizophrenia.

• Multiple sclerosis and progressive forms of neurological disease
• Epilepsy and migraine management
• ADHD, major depressive disorder, and bipolar disorder
• Research aimed at improving symptom control, quality of life, and functional outcomes

In Cluj Napoca, this area combines brain health research with studies of emotional and behavioral well-being.

Skin diseases and allergic disorders are another visible part of the trial portfolio. Research includes atopic dermatitis, alopecia areata, urticaria, bullous pemphigoid, and seasonal allergic rhinitis, with studies designed to ease symptoms and improve skin comfort.

• Atopic dermatitis and plaque psoriasis
• Alopecia areata and autoimmune skin conditions
• Chronic urticaria and allergy-related disorders
• Trials testing new approaches for inflammation, itch, and visible skin disease

These studies often aim to offer better control for conditions that can be both physically uncomfortable and emotionally burdensome.

The city’s research activity also includes infectious disease and immunology studies. Trials cover COVID-19, hepatitis B, HIV-1 infection, Clostridioides difficile infection, and other immune-related infections, often with the goal of better prevention or treatment support.

• Viral infections such as COVID-19, hepatitis B, and HIV
• Bacterial and fungal infections, including difficult-to-treat cases
• Immune deficiency and infection-related complications
• Studies focused on improving infection control and reducing serious complications

These trials show continued attention to both common and complex infectious conditions.

Several trials address endocrine and metabolic disorders, reflecting growing interest in diseases linked to hormones, metabolism, and body weight. Research includes type 2 diabetes, acromegaly, thyroid cancer, obesity, and hypertriglyceridemia.

• Type 2 diabetes and glycemic control
• Obesity and related metabolic risk
• Hormonal disorders such as acromegaly
• Studies evaluating better disease control and reduced long-term complications

These projects support a broader effort to improve chronic disease management across metabolism and hormone-related health.

Research in urinary and reproductive health includes both cancer and non-cancer conditions. Trials focus on prostate cancer, bladder cancer, renal cell carcinoma, benign prostatic hyperplasia, and chronic kidney disease, including studies that may improve treatment precision.

• Prostate cancer, including advanced and recurrent disease
• Bladder cancer and kidney cancer
• Benign prostatic hyperplasia and kidney-related disorders
• Trials seeking better cancer control and improved urinary tract health

These studies are important for patients needing more effective and better-tolerated treatment options.

Cluj Napoca also supports a wide range of specialized studies in rare diseases and complex blood-related conditions. This includes research in hemophilia, myelofibrosis, thrombocytopenia, amyloidosis, and other uncommon disorders that often need targeted approaches.

• Hemophilia and thrombocytopenia
• Myelofibrosis and related marrow disorders
• Amyloidosis and other rare systemic diseases
• Studies aimed at finding better symptom control and safer long-term care

These trials are especially valuable where treatment choices are limited and specialized expertise is needed.